About Us
Scientific Advisors
Our Scientific Advisors include renowned global academic and clinical leaders in diseases of the gastrointestinal tract, liver, pancreas, skin and lung fibrosis and cancers.
Professor Massimo Pinzani, MD, PhD, FAASLD, FRCP
Professor Massimo Pinzani, MD, PhD, FAASLD, FRCP
Massimo Pinzani co-founded Engitix in 2016 and serves on the Board of Directors. He is Scientific Director at UPMC-ISMETT and Emeritus Professor of Medicine at University College London. He is a clinical and translational hepatologist, renowned globally as an academic leader in liver fibrosis and HCC.
Alex Lugovskoy, PhD
Alex Lugovskoy, PhD
Alex is the CEO of Diagonal Therapeutics and Entrepreneur-in-Residence at Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.
Adrian S. Ray, PhD
Adrian S. Ray, PhD
Adrian Ray has over two decades experience in biotech working at Gilead, Nimbus, Morphic and, most recently, serving as Chief Scientific Officer at Third Harmonic Bio. He has provided leadership for small molecule drug discovery, nonclinical development and translation across therapeutic areas contributing to numerous IND and successful worldwide registrational filings.
Doug Thorburn, MD
Doug Thorburn, MD
Doug Thorburn is Professor of Medicine at the UCL Institute for Liver and Digestive Health London, UK. He is Clinical Director for the Liver Transplantation, HPB, Hepatology, Endoscopy and Gastroenterology services at the Royal Free Hospital with a research focus in autoimmune and cholestatic liver diseases.
Scott Turner, PhD
Scott Turner, PhD
Scott Turner is currently the Chief Scientific Officer at Arda Therapeutics. Prior to joining Arda, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and spearheaded the development of their anti-fibrotic pipeline. His innovative approaches, including pioneering the use of single-cell data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. Prior to Pliant, Scott lead research and development at KineMed Inc. a platform technology company developing translational biomarkers in fibrosis and metabolic disease. Scott received a PhD from University of California, Berkeley in Nutritional Sciences and Toxicology.
Emmanuel Tsochatzis, MD, MSC, FEBTM, FRCP, PHD
Emmanuel Tsochatzis, MD, MSC, FEBTM, FRCP, PHD
Emmanuel Tsochatzis is Professor and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London. He leads the specialist multidisciplinary service in non-alcoholic fatty liver disease (NAFLD) and his research interests include NAFLD, cirrhosis and portal hypertension and non-invasive assessment of liver fibrosis.
Tu Vinh Luong, MD, FRCPATH
Tu Vinh Luong, MD, FRCPATH
Tu Vinh Luong is Consultant Liver, HPB and GI Histopathologist at the Royal Free Hospital, London, and Honorary Associate Professor at the UCL Institute for Liver and Digestive Health, London. She is a member of the UCL-RFH Biobank Ethical Review Committee (B-ERC-RFH). Special research interests include liver fibrosis, steatosis and HCC.
Antonio Di Sabatino, MD
Antonio Di Sabatino, MD
Antonio Di Sabatino is Professor of Internal Medicine at the University of Pavia and Director of the Internal Medicine Division of the San Matteo Hospital Foundation, Pavia, Italy. His primary research interests lie in the field of translational medicine and include gut fibrosis, inflammatory bowel disease and immune-mediated/neoplastic gastrointestinal disorders.
Hendrik-Tobias Arkenau, MD, PhD, FRCP
Hendrik-Tobias Arkenau, MD, PhD, FRCP
Hendrik-Tobias Arkenau is the Executive Medical Director of the Sarah Cannon Research Institute UK (SCRI UK) and Clinical Lead for the Hospital Corporation of America International Cancer Service Line. Since founding the SCRI UK in 2010, he has built a portfolio of over 180 early-stage cancer clinical trials. He is a Fellow of the Royal College of Physicians.
Giuseppe Fusai, MD
Giuseppe Fusai, MD
Giuseppe Fusai is a Professor of Surgery at UCL and a consultant hepatic pancreatic biliary surgeon and President of the Italian Medical Society of Great Britain. His primary clinical and academic interest is in oncological surgery and treatment modalities for patients with advanced disease.
